next-generation sequencing hub

NGS market analysis and updates

Next-generation sequencing (NGS) is becoming more affordable and accessible for many, holding great potential to revolutionise healthcare through clinical applications such as non-invasive prenatal testing (NIPT), to detect cancer mutations for disease diagnosis and treatment decisions, genetic testing and infectious disease testing.

Clearstate offers market data, forecasts, and trend predictions to give you the insight on the NGS market which is set to be the fastest-growing IVD market segment in many countries. Our NGS hub is regularly updated to share our findings on this emerging IVD market segment to help prepare your business for the expanding role of NGS in clinical diagnostics.

Inquire now

next-generation sequencing updates by Clearstate

What is next-generation sequencing (NGS)?

Next-generation sequencing (NGS) is a high-throughput method used to obtain the sequence of nucleotides in entire genomes or specific gene regions. Clinical applications of NGS include non-invasive prenatal testing (NIPT), cancer testing, genetic testing and infectious disease testing.

Explore the latest NGS market insights

From market news to analysis, our articles provide concise and up-to-date information about latest in NGS market developments driving the rapid growth of NGS adoption. Uncover the challenges and opportunities ahead as the technology triggers a shift in healthcare and clinical diagnosis. Understand the impact of the emergence of NGS on the use of other competing diagnostic technologies in molecular and tissue diagnostics, and examine the challenges to implementing NGS at a wider scale in healthcare, including at smaller laboratories.

Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Across Europe, there are varying levels of laboratory infrastructure capacity supporting NGS testing and integration of NGS testing in cancer care.

Larger gene panels are the predominant NGS testing strategy in EU5

The growing number of biomarkers for which oncologists need information for treatment decision-making has necessitated a shift toward more comprehensive genomic profiling through next-generation sequencing (NGS).

Most-commonly tested cancer biomarkers using NGS in Europe: RAS, BRAF, EGFR

Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR

With more precision oncology treatments introduced in the market, and a growing number of actionable biomarkers, next-generation sequencing (NGS) is becoming increasingly important in detecting multiple mutations and biomarkers.

The fastest-growing areas for LATAM’s next-generation sequencing market

We estimate that NGS markets in LATAM countries will grow at a compound annual growth rate (CAGR) of between 5.8 and 15.7% between 2022 and 2025. Explore our key forecasts to stay ahead of market changes and inform your mid-term strategy.

The fastest-growing areas for APAC’s next-generation sequencing market

We estimate that APAC’s NGS instrument and testing markets will grow at a compound annual growth rate (CAGR) of between 14 and 15% between 2022 and 2025. Explore our key forecasts to stay ahead of market changes and inform your mid-term strategy.

Covid-19: Three purchasing behaviour trends at molecular labs (Asia-Pacific)

Covid-19 has not only impacted test volumes but also spurred changes in test practices and purchasing behaviour in Asia-Pacific’s (APAC’s) molecular diagnostics (MDx) labs.

Clearstate newsletter

Sign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts.